AC Immune jumps after Parkinson's treatment shows promise in mid-stage study

AC Immune SA

11/12/2025 12:52

** Shares of drug developer AC Immune ACIU.O soar 45.9% to $4.07 premarket

** Co says its treatment for Parkinson's disease showed positive safety and efficacy results in a mid-stage trial

** Parkinson's disease is a movement disorder of the nervous system that worsens over time

     ** Co says the therapy, ACI-7104.056, induced a robust antibody response against the immunizing a-syn target antigen

** The therapy also showed stabilization of disease-relevant biomarkers in the central nervous system, suggesting slowing of Parkinson's disease- ACIU

** ACI-7105.056 is generally safe and well-tolerated, co says

** Co to seek regulatory feedback on ACI-7104.056 to potentially accelerate towards registration

** Up to last close, stock up 3.3% YTD

 (Reporting by Sneha S K)

 ((Sneha.SK@thomsonreuters.com;))